Cargando…

A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease

Steroid-refractory (SR) acute graft-versus-host disease (aGvHD) remains a significant complication after allogeneic hematopoietic cell transplantation. Systemic corticosteroids are first-line therapy for aGvHD, but apart from ruxolitinib, there are no approved treatments for SR aGvHD. Vedolizumab is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fløisand, Yngvar, Schroeder, Mark A., Chevallier, Patrice, Selleslag, Dominik, Devine, Steven, Renteria, Anne S., Mohty, Mohamad, Yakoub-Agha, Ibrahim, Chen, Chunlin, Parfionovas, Andrejus, Quadri, Syed, Jansson, Johan, Akbari, Mona, Chen, Yi-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486663/ https://www.ncbi.nlm.nih.gov/pubmed/34108672 http://dx.doi.org/10.1038/s41409-021-01356-0

Ejemplares similares

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Case report: Induction and maintenance of steroid-free remission with vedolizumab in a case of steroid-dependent autoimmune pancreatitis
por: Griebel, Paul, et al.
Publicado: (2023)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides
por: Sioud, Mouldy, et al.
Publicado: (2019)

Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn’s Disease: Results from the Phase 2 HUBBLE Study
por: Hyams, Jeffrey S, et al.
Publicado: (2022)

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
por: Burdge, Gemma, et al.
Publicado: (2022)

Eltrombopag in Good's Syndrome
por: Kristiansen, Håvard Anton, et al.
Publicado: (2014)

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
por: Oršić Frič, Vlasta, et al.
Publicado: (2023)

Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects
por: Xie, Ran, et al.
Publicado: (2022)

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
por: Schultz, Bob G, et al.
Publicado: (2021)

Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
por: Bremer, Sara, et al.
Publicado: (2015)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2022)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy
por: Berishvili, Ekaterine, et al.
Publicado: (2020)

Worked to the bone: antibody-based conditioning as the future of transplant biology
por: Griffin, James M., et al.
Publicado: (2022)

Recent Progress in Interferon Therapy for Myeloid Malignancies
por: Healy, Fiona M., et al.
Publicado: (2021)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Chronic Cholestatic Liver Injury Attributable to Vedolizumab
por: Stine, Jonathan G., et al.
Publicado: (2016)

A Case of Evan's Syndrome Induced by Vedolizumab
por: Jen, Henry, et al.
Publicado: (2019)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Hydroxychloroquine in Covid-19: Does the end justify the means?
por: Yakoub-Agha, Ibrahim
Publicado: (2020)

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
por: Yarur, Andres J., et al.
Publicado: (2020)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Similar Properties of Chondrocytes from Osteoarthritis Joints and Mesenchymal Stem Cells from Healthy Donors for Tissue Engineering of Articular Cartilage
por: Fernandes, Amilton M., et al.
Publicado: (2013)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
por: Kothari, Megha, et al.
Publicado: (2015)

Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
por: Trieu, Judy A., et al.
Publicado: (2017)

A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
por: Rosario, Maria, et al.
Publicado: (2017)

Use of vedolizumab in a patient with chronic and refractory pouchitis
por: Orfanoudaki, Eleni, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6s1riaucbu8e8jichc59068ltn